Transgene

Stocks

Market Closed - Euronext Paris 02:55:00 16/10/26 am AEDT			5-day change	1st Jan Change
0.6820 ^EUR	-1.16%		-0.44%	-28.96%

25/09	Transgene provides update on its operations
08/09	Transgene Expands ProBioGen Partnership With Additional License	MT

Published on 06/30/2026 at 12:35 am AEST - Modified on 06/30/2026 at 06:52 am AEST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the Transgene virtual key opinion leader event. At this time, all attendees are in a listen-only mode and a

[

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

25/09	Transgene provides update on its operations
08/09	Transgene Expands ProBioGen Partnership With Additional License	MT
03/09	Transgene jumps 20% on positive cancer vaccine data in early trial	RE
03/09	Transgene: no cases of recurrence at three years among patients treated with TG4050
03/09	Transgene And NEC Corporation Report 100% Three-Year Disease-Free Survival With TG4050 And Publish Phase 1 Results In Nature Communications	CI
30/06	Transgene SA - Special Call
25/06	Oddo BHF Stays Positive on Transgene
25/06	Positive Preclinical Data for a Transgene Vaccine
25/06	Transgene Presents Preclinical Data Demonstrating Robust Protection Against Mpox With Its Novel Scalable Cell Line?Derived MVA Vaccine Candidate TG-MVATM	CI
22/06	Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine	CI
22/06	Transgene launches a clinical trial evaluating TG4070 with nivolumab
22/06	Transgene Begins Phase 1 Trial of Non-small Cell Lung Cancer Vaccine	MT
23/05	Transgene SA Announces Board Appointments	CI
13/04	Transgene Completes Patient Randomization in Phase 2 Clinical Trial Evaluating TG4050 in Adjuvant Treatment of Head and Neck Cancer	CI
07/04	Transgene stands out following licensing agreement with NEC Bio

Duration

Period

Sector